Guillermo Sanz

1984–2025 年に発表

117
論文数
28,094
被引用数
73
h 指数
111
i10 指数

被引用数

Guillermo Sanz の年別被引用数1986 年: 被引用 1 件1987 年: 被引用 1 件1988 年: 被引用 1 件1989 年: 被引用 7 件1990 年: 被引用 4 件1991 年: 被引用 3 件1992 年: 被引用 8 件1993 年: 被引用 7 件1994 年: 被引用 2 件1995 年: 被引用 5 件1996 年: 被引用 7 件1997 年: 被引用 8 件1998 年: 被引用 22 件1999 年: 被引用 20 件2000 年: 被引用 26 件2001 年: 被引用 32 件2002 年: 被引用 50 件2003 年: 被引用 72 件2004 年: 被引用 63 件2005 年: 被引用 106 件2006 年: 被引用 120 件2007 年: 被引用 136 件2008 年: 被引用 122 件2009 年: 被引用 163 件2010 年: 被引用 163 件2011 年: 被引用 183 件2012 年: 被引用 189 件2013 年: 被引用 221 件2014 年: 被引用 208 件2015 年: 被引用 178 件2016 年: 被引用 158 件2017 年: 被引用 153 件2018 年: 被引用 145 件2019 年: 被引用 601 件2020 年: 被引用 552 件2021 年: 被引用 622 件2022 年: 被引用 496 件2023 年: 被引用 457 件2024 年: 被引用 655 件2025 年: 被引用 306 件2026 年: 被引用 4 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,844 件、この内訳の 25.2%ドイツ: 引用元論文 621 件、この内訳の 8.5%イタリア: 引用元論文 557 件、この内訳の 7.6%フランス: 引用元論文 535 件、この内訳の 7.3%イギリス: 引用元論文 501 件、この内訳の 6.8%スペイン: 引用元論文 395 件、この内訳の 5.4%オランダ: 引用元論文 260 件、この内訳の 3.6%日本: 引用元論文 239 件、この内訳の 3.3%中国: 引用元論文 235 件、この内訳の 3.2%カナダ: 引用元論文 212 件、この内訳の 2.9%スウェーデン: 引用元論文 179 件、この内訳の 2.4%オーストラリア: 引用元論文 164 件、この内訳の 2.2%
0%25.2%その他 21.6%

分野

  • Medicine83.9%
  • Biochemistry, Genetics and Molecular Biology11.9%
  • Immunology and Microbiology3%
  • Computer Science0.4%
  • Environmental Science0.1%
  • Health Professions0.1%
  • その他0.6%

トピック

  • Acute Myeloid Leukemia Research20.3%
  • Hematopoietic Stem Cell Transplantation9.2%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment6.2%
  • Acute Lymphoblastic Leukemia research4.1%
  • Epigenetics and DNA Methylation3%
  • Histone Deacetylase Inhibitors Research2.8%
  • その他54.4%

共著者

全論文

検索で開く
  1. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Akifumi Takaori‐Kondo, Takayuki Ishikawa, Shigeru Chiba, Senji Kasahara, Yasushi Miyazaki, Agnès Viale, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Kazuma Ohyashiki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Eva Hellström‐Lindberg, Elli Papaemmanuil - NEJM Evidence 2022 被引用: 813

  2. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Teresa Vallespı́, Arjan A. van de Loosdrecht, Ulrich Germing, Detlef Haase - Blood 2012 被引用: 3,140

  3. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Boultwood, Fábio Pires de Souza Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori‐Kondo, Toru Kiguchi, Chantana Polprasert, John M. Bennett, Virginia M. Klimek, Michael R. Savona, Monika Beličková, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Adès, Matteo Giovanni Della Porta, Harold K. Elias, Alexandra Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna Neuberg, Kristen E. Stevenson, Kamal Menghrajani, Kelly L. Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil - Nature Medicine 2020 被引用: 636

  4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2009 被引用: 2,640

  5. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , - Blood 1997 被引用: 4,457

  6. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2017 被引用: 376

  7. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux - Blood 2023 被引用: 92

  8. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    著者: , , , , , , , , , , , , , , , , , , , , , - Blood 2013 被引用: 667

  9. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 被引用: 361

  10. Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesco Passamonti, Fabio Ciceri, Niccolò Bolli, Alessandro Rambaldi, Wolfgang Kern, Shahram Kordasti, Françesc Solé, Laura Palomo, Guillermo Sanz, Armando Santoro, Uwe Platzbecker, Pierre Fenaux, Luciano Milanesi, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta - Journal of Clinical Oncology 2021 被引用: 225

  11. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Niccolò Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, María Díez‐Campelo, Guillermo Sanz, Françesc Solé, Wolfgang Kern, Uwe Platzbecker, Lionel Adès, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta - Journal of Clinical Oncology 2023 被引用: 111

  12. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matteo Della Porta, Kety Huberman, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Seishi Ogawa, Michaëla Fontenay, Joop H. Jansen, José Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström‐Lindberg, Elli Papaemmanuil - Blood 2024 被引用: 49

  13. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 110

  14. Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 958

  15. Molecular taxonomy of myelodysplastic syndromes and its clinical implications

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matteo Giovanni Della Porta, Pierre Fenaux, Monika Beličková, Michael R. Savona, Virginia M. Klimek, Fábio Pires de Souza Santos, Jacqueline Boultwood, Ιoannis Kotsianidis, Valeria Santini, Françesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee‐Yung Shih, Michaëla Fontenay, Joop H. Jansen, José Cervera, Norbert Gattermann, Benjamin L. Ebert, Rafael Bejar, Luca Malcovati, Seishi Ogawa, M. Cazzola, Eva Hellström‐Lindberg, Elli Papaemmanuil - Blood 2024 被引用: 73

  16. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2010 被引用: 586

  17. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆

    著者: , , , , , - Annals of Oncology 2020 被引用: 170

  18. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2011 被引用: 480

  19. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

    著者: , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 被引用: 196

  20. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2018 被引用: 102

  21. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2

    著者: , , , , , , , , - Future Oncology 2023 被引用: 36

  22. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

    著者: , , , , , , , , , , , , , , , - Leukemia & lymphoma/Leukemia and lymphoma 2021 被引用: 26

  23. Time-dependent changes in mortality and transformation risk in MDS

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Arjan A. van de Loosdrecht, Ulrich Germing, Detlef Haase, Peter L. Greenberg - Blood 2016 被引用: 175

  24. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 被引用: 124